Additional Proxy Soliciting Materials (definitive) (defa14a)
June 04 2021 - 7:30AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 90549
SCHEDULE
14A
(RULE
14a-101)
INFORMATION
REQUIRED IN PROXY STATEMENT
SCHEDULE
14A INFORMATION
Proxy
Statement Pursuant to Section 14(a) of the
Securities
Exchange Act of 1934
Filed
by the Registrant
|
[X]
|
Filed
by a Party other than the Registrant
|
[ ]
|
|
|
Check
the appropriate box:
|
|
[ ]
|
Preliminary
Proxy Statement
|
[ ]
|
Confidential,
For Use of the Commission Only (as permitted by Rule 14a–6(e)(2))
|
[ ]
|
Definitive
Proxy Statement
|
[X]
|
Definitive
Additional Materials
|
[ ]
|
Soliciting
Material under Rule 14a-12
|
Advaxis,
Inc.
(Name
of Registrant as Specified in its Charter)
(Name
of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment
of Filing Fee (Check the appropriate box):
[X]
|
No
fee required.
|
[ ]
|
Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
|
(1)
|
Title
of each class of securities to which transaction applies:
|
|
|
|
|
(2)
|
Aggregate
number of securities to which transactions applies:
|
|
|
|
|
(3)
|
Per
unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):
|
|
|
|
|
(4)
|
Proposed
maximum aggregate value of transaction.
|
|
|
|
|
(5)
|
Total
fee paid:
|
|
|
|
|
|
|
[ ]
|
Fee
paid previously with preliminary materials:
|
|
|
|
|
[ ]
|
Check
box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its
filing.
|
|
|
(1)
|
Amount
previously paid:
|
|
|
|
|
(2)
|
Form,
Schedule or Registration Statement No.:
|
|
|
|
|
(3)
|
Filing
Party:
|
|
|
|
|
(4)
|
Date
Filed:
|
|
|
|
|
Advaxis,
Inc., a Delaware corporation (“Advaxis” or the “Company”), is filing materials contained in this Schedule 14A
with the U.S. Securities and Exchange Commission (the “SEC”) as definitive additional materials pursuant to Rule 14a-6(b)
under the Securities Exchange Act of 1934, as amended, in connection with the solicitation of proxies by the Board of Directors for the
Company’s Annual Meeting of Stockholders held on June 3, 2021 (the “Annual Meeting”). On April 21, 2021, Advaxis filed
a definitive proxy statement (the “Proxy Statement”) and a definitive form of proxy card with the SEC in connection with
the Annual Meeting.
Certain
Information Disclosed in the Current Report on Form 8-K the Company Filed with the SEC on June 4, 2021 (the “Form 8-K”)
As
disclosed in the Form 8-K, at the Annual Meeting held on June 3, 2021, the Company’s stockholders approved Proposals 1, 4 and 6
as set forth in the Proxy Statement. Proposal 2 was voted upon and was not approved by the Company’s stockholders.
In
addition, as disclosed in the Form 8-K, a proposal to authorize the adjournment of the Annual Meeting to June 17, 2021 to solicit additional
proxies to vote in favor of Proposal 3 and Proposal 5 (the “Adjournment Proposal”) was approved by the stockholders. Based
on the approval of the Adjournment Proposal, the Annual Meeting was adjourned to June 17, 2021, at 10:00 a.m. Eastern Time with respect
to Proposal 3, to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock
split of the Company’s common stock at a ratio determined by the Board of Directors within a range of one-for-five to one-for-fifteen,
without reducing the authorized number of shares of the Company’s common stock, to be effected in the sole discretion of the Board
of Directors at any time within one year of the date of the Annual Meeting without further approval or authorization of the Company’s
stockholders, and Proposal 5, to ratify and approve the prior amendment to the Company’s 2015 Incentive Plan, which was adopted
following the 2020 Annual Meeting of Stockholders, to increase the total number of shares of common stock authorized for issuance thereunder
from 877,744 shares to 6,000,000 shares.
The
adjourned Annual Meeting will be held at the same virtual meeting location, on June 17, 2021 at 10:00 am Eastern Time at www.virtualshareholdermeeting.com/adxs2021.
This will enable the Company’s stockholders of record as of the record date, which was April 15, 2021, additional time to consider
and vote on Proposals 3 and 5, and enable the Company’s proxy solicitor, Alliance Advisors, more time to assist the Company with
the solicitation of stockholder votes on Proposals 3 and 5.
At
the adjourned Annual Meeting on June 17, 2021, stockholders will be deemed to be present in person and vote at such adjourned meeting
in the same manner as disclosed in the Proxy Statement and mailed to the stockholders. Valid proxies submitted prior to the reconvened
Annual Meeting will continue to be valid for the upcoming reconvened Annual Meeting, unless properly changed or revoked prior to votes
being taken at such reconvened Annual Meeting.
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Sep 2023 to Sep 2024